H.R. 8857 · 119th Congress · Health
Next GEN Act of 2026
- IntroducedMay 15, 2026 Done
- CommitteeReferred to 2 committees Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 201 wordsH.R. 8857 · Introduced in House · May 15, 2026
This Act may be cited as the Next Generation Medicines Act of 2026 or the Next GEN Act of 2026 .
(a) In general. Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended— (1) in paragraph (1)(A)(ii), by inserting (or, in the case of an engineered cyclic peptide (as defined in paragraph (5)), 11 years) after 7 years ; and (2) by adding at the end the following new paragraph: (5) Engineered cyclic peptide defined In this subsection, the term engineered cyclic peptide means a polymer that— (A) is composed principally of amino acids; (B) contains not less than 1 cyclic structure produced through head-to-tail cyclization, head-to-side-chain cyclization, side-chain-to-tail cyclization, or side-chain-to-side-chain cyclization; (C) contains not more than 40 amino acids; (D) was identified for development using a genetically encoded library screening method; (E) is not naturally derived; and (F) is orally administered, inhaled, or otherwise self-administered. .
(b) Effective date. The amendments made by this section shall apply with respect to lists published under section 1192(a) of the Social Security Act ( 42 U.S.C. 1320f–1(a) ) on or after the date of the enactment of this section.
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
1 organization · 2 filings · Q2 2026–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Merck & Co., Inc
2 of 2 quarters
“Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.”
$8.8M lobbying spend in 2026 to date, all issuesQ3 2026 filing
Organizations that named H.R. 8857 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- May 15, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- May 15, 2026Introduced in House